By Fineline Cube 
US-based Guided Therapeutics, Inc. (OTCMKTS: GTHP), a developer of rapid, painless testing platforms based on patented biophotonic technology, announced it has received a USD 100,000 payment from China’s Shandong Yaohua Medical Instrument Corporation (SMI) through an investment partner. This payment marks the first in a series of planned transactions aimed at extending the collaboration agreement between GTHP and SMI. The goal is to commercialize the LuViva Advanced Cervical Scan in China following anticipated regulatory approval, expected by September 2025.
LuViva Advanced Cervical Scan
LuViva, Guided Therapeutics’ flagship product, is a non-invasive device designed to detect cervical disease instantly and at the point of care. In a multicenter clinical trial involving high-risk women, LuViva demonstrated the ability to detect cervical cancer up to two years earlier than conventional methods. This innovation underscores the potential of biophotonic technology in advancing early disease detection.
Clinical Trial and Regulatory Progress
SMI, Guided Therapeutics’ exclusive manufacturing and distribution partner in China, completed LuViva’s regulatory clinical trial in November 2023. The trial data was released in April 2024. Guided Therapeutics is now focused on securing the necessary regulatory approvals to bring this groundbreaking technology to the Chinese market.-Fineline Info & Tech